European Commission Grants Orphan Medicinal Product Designation for CAT – 1004 , Catabasis Pharmaceuticals’ Investigational Therapy for the Treatment of Duchenne Muscular Dystrophy
You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.
